

	IgG4 anti-Nfasc155	IgG4 anti-CNTN1	IgG4 anti-Caspr1	Seronegative CIDP
Number	15	10	2	100
Age (years)	54 (47-64) [£]	63 (55-75)	53 and 68	66 (55-72)
Female / Male	8/7	2/8	0/2	43/57
Sub-acute onset	6 (40%) ^{£££}	9 (90%)*, ^{£££}	2 (100%) ^{£££}	4 (4%)
Muscle weakness	12 (80%)	8 (80%)	2 (100%)	85 (85%)
Sensory deficiency	15 (100%)	10 (100%)	2 (100%)	94 (94%)
Sensory ataxia	15 (100%) ^{£££}	9 (90%)	1 (50%)	53 (53%)
Postural tremor	10 (67%) ^{££}	4 (40%)	0	22 (22%)
Cranial nerve involvement	2 (13%)	6 (60%)*, ^{£££}	2 (100%) ^{£££}	15 (15%)
Pain	4 (28%)	5 (50%)	1 (50%)	33 (33%)
Respiratory failure	0	2 (20%)	2 (100%) ^{££}	14 (14%)
Membranous glomerulonephritis	0	6 (60%) ^{***, £££}	0	0
ONLS				
-Total	6 (4-7)	10 (7-12) **, ^{££}	10 and 5	3 (2-4)
-Arm	2 (1-3)	4 (4-5) **, ^{££}	4 and 2	1 (0-2)
-Leg	4 (2-4) ^{££}	6 (5-7) **, ^{£££}	6 and 3	2 (1-3)
Rankin	4 (2-4)	4.5 (4-5) ^{£££}	5 and 4	2 (1-3)
CSF protein level (g/l)	2.82 (1.7-4.3) [£]	1.9 (1.1-2.4)	12 and 2.5 [£]	0.6 (0.5-0.9)
Good response to:				
- IVIg	3/15 (20%) ^{£££}	1/10 (10%) ^{£££}	0/2 ^{£££}	67/84 (80%)
- Steroids	8/13 (62%)	4/8 (50%)	0/1	26/38 (68%)
- Plasma exchange	5/9 (56%)	2/6 (33%)	0/1	4/6 (67%)
- Rituximab	8/8 (100%)	5/6 (83%)		5/5 (100%)

Table 1: Clinical features of CIDP patients with or without antibodies against the node of Ranvier.

Quantitative data are expressed in median (interquartile range). ONLS, overall neuropathy limitation scale; CSF, cerebrospinal fluid; IVIg, intravenous immunoglobulins.

Comparison with seronegative CIDP. p-Values: ^{£££} p < 0.001, ^{££} p < 0.01, [£] p < 0.05.

Comparison between CIDP with antibodies against CNTN1 and Nfasc155: ^{***} p < 0.001, ^{**} p < 0.01, ^{*} p < 0.05